Literature DB >> 35132455

Bilateral Atypical Femur Fractures After Denosumab in a Bisphosphonate Naive Patient: A Case Report.

Jeremy Keng Meng Goh1, Joyce Suang Bee Koh2, Alvin Choong Meng Ng3, Meng Ai Png4, Tet Sen Howe2.   

Abstract

A case report of bilateral atypical femur fractures (AFF) in a bisphosphonate naive patient. A 62-year-old female bisphosphonate naive patient was started on denosumab for osteoporosis. Approximately 3 years later she complained of right hip pain and was found to have a bilateral incomplete AFFs. She was asymptomatic on the left lower limb. Patient was managed conservatively and placed on protected weight bearing on both legs. Symptoms subsequently resolved over a period of 3 months, although radiographic findings remained at approximately 1 year. AFFs may be associated with patients on denosumab therapy even without a prior history of bisphosphonate use. Patients should be counselled appropriately and monitored for such complications.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Atypical femur fractures; Bisphosphonates; Denosumab; Osteoporosis; Prolia; Stress fractures

Mesh:

Substances:

Year:  2022        PMID: 35132455     DOI: 10.1007/s00223-022-00952-6

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.000


  20 in total

1.  Bilateral atypical femoral fractures in a patient prescribed denosumab - a case report.

Authors:  Robin N Thompson; Ciara L Armstrong; Gary Heyburn
Journal:  Bone       Date:  2013-12-31       Impact factor: 4.398

Review 2.  Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research.

Authors:  Elizabeth Shane; David Burr; Bo Abrahamsen; Robert A Adler; Thomas D Brown; Angela M Cheung; Felicia Cosman; Jeffrey R Curtis; Richard Dell; David W Dempster; Peter R Ebeling; Thomas A Einhorn; Harry K Genant; Piet Geusens; Klaus Klaushofer; Joseph M Lane; Fergus McKiernan; Ross McKinney; Alvin Ng; Jeri Nieves; Regis O'Keefe; Socrates Papapoulos; Tet Sen Howe; Marjolein C H van der Meulen; Robert S Weinstein; Michael P Whyte
Journal:  J Bone Miner Res       Date:  2013-10-01       Impact factor: 6.741

3.  Atypical femoral fracture in a patient treated with denosumab.

Authors:  Kareeann Sok Fun Khow; Tuck Yean Yong
Journal:  J Bone Miner Metab       Date:  2014-07-05       Impact factor: 2.626

4.  Recurrence of bilateral atypical femoral fractures associated with the sequential use of teriparatide and denosumab: a case report.

Authors:  S K Ramchand; C Y Chiang; R M Zebaze; E Seeman
Journal:  Osteoporos Int       Date:  2015-10-12       Impact factor: 4.507

5.  Conservative treatment of recurrent symptoms of an incomplete, atypical femoral fracture associated with glucocorticoid, bisphosphonate, and denosumab therapy in a patient with chronic obstructive pulmonary disease.

Authors:  Kun-Hung Lai; Chih-Yung Chiang; Rong-Sen Yang; Kai-Chiang Yang; Chang-Chin Wu
Journal:  Acta Clin Belg       Date:  2018-10-19       Impact factor: 1.264

6.  Atypical femoral fractures bilaterally in a patient receiving denosumab.

Authors:  Efstathios Drampalos; George Skarpas; Nikos Barbounakis; Ioannis Michos
Journal:  Acta Orthop       Date:  2013-10-31       Impact factor: 3.717

7.  Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review.

Authors:  Momoko Takahashi; Yukinori Ozaki; Rika Kizawa; Jun Masuda; Kentaro Sakamaki; Keiichi Kinowaki; Taro Umezu; Chihiro Kondoh; Yuko Tanabe; Nobuko Tamura; Yuji Miura; Takashi Shigekawa; Hidetaka Kawabata; Noriyuki Baba; Haruo Iguchi; Toshimi Takano
Journal:  BMC Cancer       Date:  2019-10-22       Impact factor: 4.430

8.  Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.

Authors:  Dennis M Black; Erik J Geiger; Richard Eastell; Eric Vittinghoff; Bonnie H Li; Denison S Ryan; Richard M Dell; Annette L Adams
Journal:  N Engl J Med       Date:  2020-08-20       Impact factor: 91.245

9.  Atypical fracture of the femur in a patient using denosumab--a case report.

Authors:  Jörg Schilcher; Per Aspenberg
Journal:  Acta Orthop       Date:  2014-01-24       Impact factor: 3.717

10.  The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension.

Authors:  Henry G Bone; Roland Chapurlat; Maria-Luisa Brandi; Jacques P Brown; Edward Czerwinski; Marc-Antoine Krieg; Dan Mellström; Sebastião C Radominski; Jean-Yves Reginster; Heinrich Resch; Jose A Román Ivorra; Christian Roux; Eric Vittinghoff; Nadia S Daizadeh; Andrea Wang; Michelle N Bradley; Nathalie Franchimont; Michelle L Geller; Rachel B Wagman; Steven R Cummings; Socrates Papapoulos
Journal:  J Clin Endocrinol Metab       Date:  2013-08-26       Impact factor: 5.958

View more
  1 in total

1.  Incidence of Atypical Femoral Fractures in Patients on Osteoporosis Therapy-A Registry-Based Cohort Study.

Authors:  Judith Everts-Graber; Harald Bonel; Daniel Lehmann; Brigitta Gahl; HansJörg Häuselmann; Ueli Studer; Hans-Rudolf Ziswiler; Stephan Reichenbach; Thomas Lehmann
Journal:  JBMR Plus       Date:  2022-09-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.